Posted 8th June 2018 by Jane Williams
Aurélie Bayle is a Data Protection Officer at be-ys: a role she considers to be at the heart of the new legal framework for any company.
Before GDPR came into effect on 25th May 2018, she was working towards global compliance, which involved completing all the steps given by the Article 29 Data Protection Working Party, an advisory board made up of a representative from the data authority of each EU Member State, the European Data Protection Supervisor, and the European Commission. Her duties have included auditing the structures and processes, preparing the data protection impact assessments, checking the compliance of processing activities, analysing the risks of the processing in the medical area, preparing new processes and policies about data protection, and asking data processors about their own compliance.
Posted 16th April 2018 by Jane Williams
The amount of data we are creating every day has increased exponentially to match the rise in use of smart and connected devices. The internet of things has connected every aspect of our lives to the digital realm: most of these devices operate by tracking your habits, movements, preferences, voice, and more, then logging those habits online. Specifically, the collection of health data has become abundant, because most people now have or wear some sort of device to track daily patterns, steps, cycles, and more. Even our phones often default to track these things for us, whether we choose to enable the function or not.
Posted 13th March 2018 by Jane Williams
The pharmaceutical research industry is suffering from a lack of innovation, yet we see an exponential increase in new science and technologies. Open innovation, in the truest meaning, is a disruptive model that will greatly increase our joint chances of translating new research into treatments, but we need new ways of sharing and participating in collaborative drug research. Blockchain technologies can provide the digital infrastructure that allows trusted and secure transactions of research assets. Applying smart contracts on top of such infrastructure will further increase the speed of the life science ecosystem allowing exploration, co-creation, and transaction of research assets to happen in an unprecedented manner. In fact, we can’t afford to object to such a marriage between pharma open innovation and blockchain technologies.
Posted 7th February 2018 by Jane Williams
What is the blockchain?
According to a recent Forbes article: the blockchain is one of the most misunderstood technologies of 2017 (1). While most healthcare professionals have heard the term “blockchain” and are aware of the innovations in financial technology, few understand the fundamental principles behind the technology in order to speculate the impacts it will have on the healthcare industry, at hospitals, and for patients. This inability is common across sectors and can be attributed to the absence of any standard definition of blockchain technology. However, it is important that industry leaders have a firm basis for understanding it in order to foresee its impacts on their business. What follows is a list of key points for understanding the blockchain and enabling speculation on its impacts in healthcare: